Double Trigger in Patients With Low Proportion of Mature Oocytes
NCT ID: NCT04407052
Last Updated: 2020-05-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
66 participants
INTERVENTIONAL
2020-05-30
2021-02-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Double trigger
GnRH-agonist and HCG are used to trigger ovulation
Double trigger
Final follicular maturation is triggered by the coadministration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively
HCG
HCG is used to trigger ovulation
HCG trigger
Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Double trigger
Final follicular maturation is triggered by the coadministration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively
HCG trigger
Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with 6 to 15 mature follicles on the day oocyte trigger in the current IVF-ET attempt
Exclusion Criteria
* PCOS
18 Years
35 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Riyadh Fertility and Reproductive Health center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Usama M Fouda, Prof.
Role: STUDY_CHAIR
Riyadh Fertility and Reproductive Health center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Riyadh Fertility and Reproductive Health center
Giza, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Usama M Fouda, Prof.
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Zilberberg E, Haas J, Dar S, Kedem A, Machtinger R, Orvieto R. Co-administration of GnRH-agonist and hCG, for final oocyte maturation (double trigger), in patients with low proportion of mature oocytes. Gynecol Endocrinol. 2015 Feb;31(2):145-7. doi: 10.3109/09513590.2014.978850. Epub 2014 Nov 11.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Double trigger/mature oocytes
Identifier Type: -
Identifier Source: org_study_id